LOGIN  |  REGISTER
Astria Therapeutics
Assertio

Insulet to Present at Upcoming Investor Conferences

February 14, 2023 | Last Trade: US$173.42 3.15 1.85

ACTON, Mass. / Feb 14, 2023 / Business Wire / Insulet Corporation (NASDAQ: PODD) (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at two upcoming investor conferences:

  • The Raymond James & Associates 44th Annual Institutional Investors Conference in Orlando, FL on Tuesday, March 7, 2023 at 9:15 a.m. (Eastern Time)
  • The Cowen 43rd Annual Health Care Conference in Boston, MA on Wednesday, March 8, 2023 at 10:30 a.m. (Eastern Time).

To listen to the live audio webcasts of the presentations, please visit investors.insulet.com/events. Replays of the webcasts will also be available following the events.

About Insulet Corporation

Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet’s latest innovation, the Omnipod® 5 Automated Insulin Delivery System, is a tubeless automated insulin delivery system, integrated with a continuous glucose monitor to manage blood sugar with no multiple daily injections, zero fingersticks, and is fully controlled by a compatible personal smartphone. Insulet also leverages the unique design of its Pod by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across other therapeutic areas. For more information, please visit: insulet.com and omnipod.com.

©2023 Insulet Corporation. Omnipod and Omnipod 5 are registered trademarks of Insulet Corporation.

Stock Quote

Featured Stock

Chimerix

Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....

CLICK TO LEARN MORE

Featured Stock

Surmodics

Surmodics is the global leader in surface modification technologies for intravascular medical devices and a leading provider of chemical components for in vitro diagnostic immunoassay tests and microarrays. Surmodics is pursuing highly differentiated whole-product solutions that are designed to address...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page

COPYRIGHT ©2023 HEALTH STOCKS HUB